Cerevel Therapeutics Holdings, Inc. was an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses.[1]
History
Cerevel was established in October 2018.[2] The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital.[3][4]
In 2019, Cerevel appointed N. Anthony Coles as its chief executive officer.[5] In 2020, Coles led Cerevel's effort to raise $445 million for brain drugs, the third largest biotech public listing at that time (after Legend Biotech and Moderna